Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 7, 1999, Pages 625-634

  Tammemagi, Martin C ^a,c   McLaughlin, John R ^b   Bull, Shelley B ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Josephine Ford Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032803467     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Greenblatt, M. S , Bennett, W. P., Hollstein, M , and Harris, C. C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis. Cancer Res , 54. 4855-4878, 1994.
2. Harris, C. C p53: at the crossroads of molecular carcinogenesis and risk assessment Science (Washington DC), 262: 1980-1981, 1993
3. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253. 49-53, 1991.
4. Yesner, R. Pathogenesis and pathology. Clin Chest Med., 14. 17-30, 1993
5. DerSimonian, R., and Laird, N. Meta-analysis in clinical trials. Controlled Clin. Trials, 7: 177-188, 1986
6. Fleiss, J. L The statistical basis of meta-analysis. Stat. Methods Med Res., 2: 121-145, 1993
7. Mosteller, F , and Colditz, G. A Understanding research synthesis (meta-analysis). Annu Rev. Public Health, 17: 1-23, 1996.
8. Agresti, A An Introduction to Categorical Data Analysis. Wiley Series in Probability and Statistics: Applied Probability and Statistics. New York. Wiley, 1996.
9. Howe, G. Meta-analysis. In: P Greenwald, B. S. Kramer, and D L. Weed (eds), Cancer Prevention and Control, pp 273-284. New York: Marcel Dekker, Inc., 1995
10. Kondo, K., Umemoto, A., Akimoto, S., Uyama, T., Hayashi, K., Ohnishi, Y., and Monden, Y Mutations in the p53 tumour suppressor gene in primary lung cancer in Japan Biochem Biophys Res. Commun , 183: 1139-1146, 1992.
11. Kondo, K., Tsuzuki, H , Sasa, M., Sumitomo, M., Uyama, T., and Monden, Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients J. Surg. Oncol., 61: 20-26, 1996.
12. Gazzeri, S., Brambilla, E , Caron de Fromentel, C., Gouyer, V , Moro, D., Perron, P., Berger, F., and Brambilla, C. p53 genetic abnormalities and myc activation in human lung carcinoma Int J Cancer, 58: 24-32, 1994.
13. Brambilla, E., Gazzeri, S , Moro, D., Caron de Fromentel, C., Gouyer, V , Jacrot, M , and Brambilla, C. Immunohistochemical study of p53 in human lung carcinomas. Am. J. Pathol., 143: 199-210, 1993.
14. Xu, H. J., Quinlan, D. C., Davidson, A. G., Hu, S. X., Summers, C. L., Li, J., and Benedict, W. F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J. Natl. Cancer Inst., 86: 695-699, 1994.
15. Quinlan, D. C., Davidson, A G , Summers, C. L., Warden, H E , and Doshi, H M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52 4828-4831, 1992
16. Fujino, M., Dosaka-Akita, H., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer (Phila.), 76: 2457-2463, 1995
17. Dosaka-Akita, H., Shindoh, M , Fujino, M , Kinoshita, I., Akie, K., Katoh, M., and Kawakami, Y. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am. J. Clin Pathol., 102: 660-664, 1994.
18. Husgafvel-Pursiainen, K., Ridanpaa, M., Anttila, S , and Vainio, H. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures J Occup. Environ Med., 37: 69-76, 1995.
19. Ridanpaa, M., Karjalaninen, A., Anttila, S., Vainio, H., and Husgafvel-Pursiainen, K. Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. Int. J. Oncol., 5: 1109-1117, 1994.
20. Mitsudomi, T., Oyama, T , Nishida, K., Ogami, A., Osaki, T., Nakanishi, R., Sugio, K., Yasumoto, K., and Sugimachi, K. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann. Oncol., 6 (Suppl ): S9-S13, 1995.
21. Mitsudomi, T., Oyama, T., Kusano, T , Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl. Cancer Inst., 85: 2018-2023, 1993.
22. Tsai, C. M., Chang, K. T., Wu, L. H , Chen, J. Y., Gazdar, A F., Mitsudomi, T., Chen, M. H., and Perng, R P. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines Cancer Res, 56: 206-209, 1996
23. Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone, D., D'Amico, D., Bodner, S., Oie, H. K., Linnoila, R. I., Mulshine, J. L., Minna, J D., and Gazdar, A. F p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features, Oncogene, 7. 171-180, 1992.
24. Passlick, B , Izbicki, J. R , Riethmuller, G., and Pantel, K. p53 in non-small-cell lung cancer. J. Natl. Cancer Inst., 86: 801-803, 1994.
25. Passlick, B., Izbicki, J. R., Haussinger, K., Thetter, O, and Pantel, K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer J Thorac. Cardiovasc. Surg , 109 1205-1211, 1995.
26. Hall, P. A , and Lane, D. P p53 in tumour pathology: can we trust immunohistochemistry? Revisited!. J. Pathol , 172: 1-4, 1994
27. Takahashi, T., D'Amico, D., Chiba, I., Buchhagen, D. L., and Minna, J. D. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer J. Clin. Invest., 86: 363-369, 1990.
28. McDonald, J. W , Taylor, J. A , Watson, M. A , Saccomanno, G., and Devereux, T R. p53 and K-ras in radon-associated lung adenocarcinoma. Cancer Epidemiol Biomark. Prev., 4: 791-793, 1995.
29. Vahakangas, K. H , Samet, J. M., Metcalf, R. A., Welsh, J. A., Bennett, W. P., Lane, D. P., and Harris, C C Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet, 339 576-580, 1992.
30. Taylor, J A , Watson, M. A., Devereux, T R., Michels, R. Y., Saccomanno, G , and Anderson, M. p53 mutation hotspot in radon-associated lung cancer Lancet, 343: 86-87, 1994.
31. Takeshima, Y , Inai, K., Bennett, W P., Metcalf, R. A., Welsh, J. A , Yonehara, S., Hayashi, Y , Fujihara, M., Yamakido, M., Akiyama, M., Tokuoka, S , Land, C E., and Harris, C. C. p53 mutations in lung cancers from Japanese mustard gas workers. Carcinogenesis (Lond.), 15: 2075-2079, 1994
32. Takeshima, Y., Seyama, T., Bennett, W. P., Akiyama, M , Tokuoka, S., Inai, K., Mabuchi, K., Land, C. E., and Harris, C. C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors (published erratum in Lancet, 343. 1302, 1994]. Lancet, 342: 1520-1521, 1993.
33. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M J , Rosenberg, R. K., Vinocour, M., Levitt, M , Pass, H , Gazdar, A. F., and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer Science (Washington DC), 246: 491-494, 1989
34. Caamano, J , Ruggeri, B., Momiki, S., Sickler, A., Zhang, S. Y., and Klein-Szanto, A. J. Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines Am J. Pathol., 139: 839-845, 1991
35. Lehman, T. A., Bennett, W. P., Metcalf, R A , Welsh, J. A., Ecker, J , Modali, R V , Ullrich, S., Romano, J. W., Appella, E., Testa, J R., Gerwin, B. I., and Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines Cancer Res., 51: 4090-4096, 1991.
36. Bodner, S. M., Minna, J. D., Jensen, S. M , D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Buchhagen, D. L., Nau, M. M., Gazdar, A. F., and Linnoila, R I Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
37. Kashii, T , Mizushima, Y , Monno, S., Nakagawa, K , and Kobayashi, M Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J. Cancer Res. Clin. Oncol., 120: 143-148, 1994.
38. Morkve, O., and Laerum, O. D. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas. Cytometry, 12: 438-444, 1991.
39. Morkve, O , Halvorsen, O. J., Skjaerven, R., Stangeland, L., Gulsvik, A , and Laerum, O. D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas Anticancer Res, 13. 571-578, 1993.
40. Pappot, H , Francis, D , Brunner, N., Grondahl-Hansen, J., and Osterlind, K. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay relation to prognosis. Clin Cancer Res., 2. 155-160, 1996.
41. Chiba, I., Takahashi, T., Nau, M. M., D'Amico, D., Curiel, D. T , Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H., Reissman, P. T , Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene, 5: 1603-1610, 1990.
42. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A L. Increased expression of mutant forms of p53 oncogene in primary lung cancer Lancet, 335: 675-679, 1990.
43. Hiyoshi, H., Matsuno, Y., Kato, H , Shimosato, Y., and Hirohashi, S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer Jpn. J. Cancer Res , 83: 101-106, 1992.
44. Kishimoto, Y , Murakami, Y , Shiraishi, M., Hayashi, K , and Sekiya, T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res , 52: 4799-4804, 1992.
45. McLaren, R , Kuzu, I., Dunnill, M., Harris, A., Lane, D., and Gatter, K. C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66. 735-738, 1992.
46. Miller, C. W., Simon, K., Aslo, A , Kok, K., Yokota, J , Buys, C H., Terada, M., and Koeffler, H. P. p53 mutations in human lung tumors. Cancer Res, 52: 1695-1698, 1992.
47. Pavelic, Z P, Gluckman, J L., Gapany, M., Reising, J., Craven, J. M , Kelley, D. J., Pavelic, L., Gapany, S., Biddinger, P., and Stambrook, P. J. Improved immunohistochemical detection of p53 protein in paraffin-embedded tissues reveals elevated levels in most head and neck and lung carcinomas: correlation with clinicopathological parameters. Anticancer Res , 12. 1389-1394, 1992.
48. Soini, Y., Paakko, P., Nuorva, K , Kamel, D , Lane, D. P., and Vahakangas, K Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas Virchows Arch. A Pathol. Anat Histopathol, 421: 223-228, 1992.
49. Sozzi, G., Miozzo, M., Donghi, R , Pilotti, S., Cariani, C T , Pastorino, U , Della Porta, G., and Pierotti, M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung Cancer Res., 52 6079-6082, 1992.
50. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N M., and Rabbitts, P p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus Oncogene, 7. 1989-1997, 1992.
51. Suzuki, H , Takahashi, T., Kuroishi, T , Suyama, M., Ariyoshi, Y , and Ueda, R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res , 52: 734-736, 1992.
52. Volm, M., Efferth, T , and Mattem, J Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung Clinical and biological correlations. Anticancer Res., 12 11-20, 1992.
53. Bennett, W. P , Colby, T. V., Travis, W D , Borkowski, A., Jones, R. T., Lane, D. P., Metcalf, R. A., Samet, J. M., Takeshima, Y., Gu, J. R., Vahakangas, K. H., Soini, Y., Paakko, P., Welsh, J. A , Trump, B F., and Harris, C. C. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53. 4817-4822, 1993.
54. Fontanini, G , Bigini, D , Vignati, S., Macchiarini, P., Pepe, S., Angeletti, C. A., Pingitore, R., and Squartini, F. p53 expression in non small cell lung cancer: clinical and biological correlations. Anticancer Res, 13: 737-742, 1993.
55. Gosney, J. R., Butt, S. A., Gosney, M. A., and Field, J K. Exposure to cigarette smoke and expression of the protein encoded by the p53 gene in bronchial carcinoma Ann N. Y. Acad. Sci., 686: 243-248, 1993.
56. Hono, Y , Takahashi, T , Kuroishi, T., Hibi, K , Suyama, M., Niimi, T , Shimokata, K., Yamakawa, K., Nakamura, Y., Ueda, R , and Takahashi, T Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53. 1-4, 1993.
57. Klein, N., Vignaud, J. M., Sadmi, M., Plenat, F., Borelly, J., Duprez, A., Martinet, Y., and Martinet, N. Squamous metaplasia expression of proto-oncogenes and p53 in lung cancer patients. Lab. Invest., 68: 26-32, 1993
58. Marchetti, A., Buttitta, F , Merlo, G , Diella, F., Pellegrini, S., Pepe, S , Macchiarini, P., Chella, A., Angeletti, C A., Callahan, R., Bistocchi, M., and Squartini, F. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res., 53. 2846-2851, 1993
59. Nuorva, K , Soini, Y., Kamel, D., Autio-Harmainen, H., Risteli, L., Risteli, J., Vahakangas, K , and Paakko, P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas Am. J Pathol., 142: 725-732, 1993.
60. Westra, W. H., Offerhaus, G. J , Goodman, S N., Slebos, R. J., Polak, M., Baas, I O., Rodenhuis, S., and Hruban, R. H Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am. J. Surg. Pathol , 17. 213-220, 1993
61. Bongiomo, P F , Whyte, R. I., Lesser, E J., Moore, J. H., Orringer, M. B., and Beer, D G. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J. Thorac. Cardiovasc. Surg., 107: 590-595, 1994.
62. Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V , Nowak, J A., McIntire, D., Slamon, D., Gazdar, A., and Minna, J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer A preliminary report of LCSG 871 Chest, 106 (Suppl.): 377S-381S, 1994.
63. Casson, A. G , McCuaig, S., Craig, I., Ayed, A , Inculet, R., Kerkvliet, N , and O'Malley, F. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. J. Surg Oncol , 56: 13-20, 1994.
64. Ebina, M., Steinberg, S. M., Mulshine, J. L , and Linnoila. R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54 2496-2503, 1994.
65. Fontanini, G , Vignati, S., Bigini, D., Merlo, G. R., Ribecchini, A , Angeletti, C. A., Basolo, F., Pingitore, R , and Bevilacqua, G. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J. Pathol, 174: 23-31, 1994
66. Hirano, T., Franzen, B , Kato, H , Ebihara, Y., and Auer, G Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. Am. J. Pathol., 144: 296-302, 1994.
67. Isobe, T., Hiyama, K , Yoshida, Y., Fujiwara, Y., and Yamakido, M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection Jpn. J. Cancer Res , 85. 1240-1246, 1994
68. Lee, L. N., Shew, J. Y , Sheu, J. C., Lee, Y. C., Lee, W. C , Fang, M. T , Chang, H. F., Yu, C J., Yang, P C., and Luh, K T Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. Am J. Respir Crit Care Med , 150 1667-1671, 1994
69. Li, Z H , Zheng, J , Weiss, L. M , and Shibata, D c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung Am. J. Pathol , 144. 303-309, 1994
70. Nuorva, K., Makitaro, R , Huhti, E , Kamel, D., Vahakangas, K., Bloigu, R , Soini, Y., and Paakko, P. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J. Respir. Crit. Care Med , 150: 528-533, 1994.
71. Reichel, M. B , Ohgaki, H., Petersen, I , and Kleihues, P. p53 mutations in primary human lung tumors and their metastases. Mol. Carcinog., 9: 105-109, 1994.
72. Ryberg, D., Kure, E., Lystad, S., Skaug, V , Stangeland, L , Mercy, I , Borresen, A. L., and Haugen, A. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer Cancer Res., 54: 1551-1555, 1994.
73. Volm, M , Mattern, J , Hecker, S., and Pommerenke. E. Association of p53 expression with proliferative activity and poor prognosis in patients with squamous cell lung carcinomas. Int. J. Oncol., 5: 533-538, 1994.
74. Walker, C., Robertson, L. J., Myskow, M. W., Pendleton, N., and Dixon, G. R. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer, 70. 297-303, 1994.
75. Zheng, J., Shu, Q., Li, Z. H., Tsao, J. I., Weiss, L. M., and Shibata, D. Patterns of p53 mutations in squamous cell carcinoma of the lung Acquisition at a relatively early age. Am. J. Pathol., 145: 1444-1449, 1994.
76. al-Ghamdi, A. A., Sanders, C. M., Keefe, M., Coggon, D., and Maitland, N. J Human papillomavirus DNA and TP53 mutations in lung cancers from butchers. Br. J. Cancer, 72: 293-297, 1995.
77. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C. A., Basolo, F., and Bevilacqua, G Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer, 71. 1003-1007, 1995.
78. Guinee, D. G , Jr , Travis, W D., Trivers, G. E , De Benedetti, V. M., Cawley, H., Welsh, J. A., Bennett, W. P., Jett, J., Colby, T V , Tazelaar, H., Abbondanzo, S L., Pairolero, P., Trastek, V., Caporaso, N E , Liotta, L E., and Harris, C. C Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis (Lond.), 16: 993-1002, 1995
79. Harpole, D. H., Jr, Herndon, J E., II, Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995
80. Kashii, T , Mizushima, Y., Lima, C. E., Noto, H., Sato, H., Saito, H., Kusajima, Y., Kitagawa, M., Yamamoto, K., and Kobayashi, M. Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene alterations: comparison between younger and older groups Oncology, 52: 219-225, 1995.
81. Langendijk, J. A , Thunnissen, F. B., Lamers, R. J., de Jong, J. M , ten Velde, G P, and Wouters, E. F. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy Radiother. Oncol., 36: 218-224, 1995.
82. Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., and Hong, W. K Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J. Clin. Oncol., 13: 1893-1903, 1995.
83. Melhem, M. F., Law, J. C., el-Ashmawy, L., Johnson, J. T., Landreneau, R. J., Srivastava, S., and Whiteside, T. L. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am. J. Pathol., 146: 1170-1177, 1995.
84. Top, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R., Visser, S., and Rodenhuis, S. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int. J Cancer, 64: 83-91, 1995.
85. Wang, X., Christiani, D. C., Wiencke, J. K., Fischbein, M., Xu, X., Cheng, T. J , Mark, E., Wain, J. C., and Kelsey, K T. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol. Biomark. Prev., 4: 543-548, 1995.
86. Wiethege, T., Voss, B., and Muller, K. M. p53 accumulation and proliferating-cell nuclear antigen expression in human lung cancer. J. Cancer Res. Clin Oncol , 121: 371-377, 1995.
87. Wild, C. P., Ridanpaa, M , Anttila, S., Lubin, R , Soussi, T., Husgafvef-Pursiainen, K., and Vainio, H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer, 64: 176-181, 1995.
88. Dalquen, P , Sauter, G , Torhorst, J., Schultheiss, E., Jordan, P., Lehmann, S., Soler, M , Stulz, P, Mihatsch, M J., and Gudat, F Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol., 178: 53-58, 1996.
89. Kwa, H. B., Michalides, R. J , Dijkman, J. H., and Mooi, W. J. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer, 14: 207-217, 1996
90. Lung, M. L., Wong, M. P., Skaanild, M. T , Fok, C. L., Lam, W K , and Yew. W. W. p53 mutations in non-small cell lung carcinomas in Hong Kong. Chest, 109: 718-726, 1996.
91. Nishio, M., Koshikawa, T., Kuroishi, T., Suyama, M., Uchida, K., Takagi, Y., Washimi, O., Sugiura, T., Ariyoshi, Y., Takahashi, T., and Ueda, R. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers J. Clin. Oncol., 14: 497-502, 1996.
92. Shipman, R., Schraml, P., Colombi, M., Raefle, G , Dalquen, P., and Ludwig, C. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer. Eur. J. Cancer, 32A: 335-341, 1996.
93. Takeshima, Y , Nishisaka, T., Kawano, R., Kishizuchi, K., Fujii, S., Kitaguchi, S., and Inai, K. p16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma. Jpn. J. Cancer Res , 87: 134-140, 1996
94. Apolmario, R M., van der Valk, P., de Jong, J. S., Deville, W., van Ark-Otte, J., Dingemans, A. M , van Mourik, J C., Postmus, P. E., Pinedo, H. M., and Giaccone, G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J. Clin. Oncol., 15: 2456-2466, 1997.
95. Esposito, V., Baldi, A., De Luca, A., Micheli, P, Mazzarella, G., Baldi, F., Caputi, M , and Giordano, A. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol., 28: 233-237, 1997
96. Kennedy, M M , Lamb, D., King, G., and Kerr, K. M Cell proliferation, cell loss and expression of bcl-2 and p53 in human pulmonary neoplasms Br. J. Cancer, 75: 545-547, 1997
97. Wu-Williams, A H , and Samet, J. M. Lung cancer and cigarette smoking. In: J. M. Samet (ed.), Epidemiology of Lung Cancer, pp. 71-108 New York: Marcel Dekker, Inc , 1994.
98. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
99. Levine, A. J p53, the cellular gatekeeper for growth and division Cell, 88: 323-331, 1997.
100. Mountain, C. F. A new international staging system for lung cancer. Chest, 89 (Suppl.): 225S-233S, 1986.
101. Beahrs, O H , American Joint Committee on Cancer, and American Cancer Society. Manual for Staging of Cancer, Ed 3. Philadelphia: Lippincott, 1988.
102. Beahrs, O. H , American Joint Committee on Cancer, and American Cancer Society. Manual for Staging of Cancer, Ed 4. Philadelphia: Lippincott, 1992.
103. WHO. The World Health Organization Histological Typing of Lung Tumours, second edition. Am. J. Clin. Pathol., 77: 123-136, 1982.
104. Kelsey, J. L , Whittemore, A. S., Evans, A. S , and Thompson, W D. Methods in Observational Epidemiology Monographs in Epidemiology and Biostatistics, Vol. 26, pp. 348-352. New York: Oxford University Press, 1996.
105. Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T., Hollstein, M , Harris, C. C., and Montesano, R. IARC Database of p53 gene mutations in human tumors and cell lines updated compilation, revised formats and new visualisation tools. Nucleic Acids Res., 26: 205-213, 1998.